ACHV — Achieve Life Sciences Income Statement
0.000.00%
Last trade - 00:00- $81.86m
- $57.33m
Annual income statement for Achieve Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 14.8 | 33.1 | 40.8 | 27.3 | 39.4 |
| Operating Profit | -14.8 | -33.1 | -40.8 | -27.3 | -39.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -14.7 | -33.2 | -42.4 | -29.8 | -39.8 |
| Net Income After Taxes | -14.7 | -33.2 | -42.4 | -29.8 | -39.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -14.7 | -33.2 | -42.4 | -29.8 | -39.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -14.7 | -33.2 | -42.4 | -29.8 | -39.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.42 | -4.08 | -4 | -1.5 | -1.23 |